Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MLYCD | O95822 | 6/20 | 0.48 |
| ▸ | TACR1 | P25103 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimorpholamine SCHEMBL2689742 | 0.98 | POLB (0.57) | POLBHTTSMN1; SMN2LMNAMLYCD | |
| SCHEMBL8605252 | 0.98 | POLB (0.60) | POLBHTTSMN1; SMN2LMNAMLYCD | |
| SCHEMBL12472375 | 0.87 | POLB (0.64) | POLBHTTSMN1; SMN2LMNAMLYCD | |
| SCHEMBL9469495 | 0.85 | POLB (0.50) | POLBHTTSMN1; SMN2LMNAMLYCD | |
| SCHEMBL8605240 | 0.83 | POLB (0.50) | POLBHTTSMN1; SMN2LMNAMLYCD | |
| SCHEMBL715792 | 0.80 | POLB (0.46) | POLBHTTSMN1; SMN2LMNAMLYCD | |
| SCHEMBL14229118 | 0.80 | L3MBTL1 (0.52) | TACR1HPGDMEN1KMT2A | |
| SCHEMBL12086329 | 0.80 | POLB (0.86) | POLBHTTSMN1; SMN2LMNAMLYCD | |
| SCHEMBL11506406 | 0.79 | HTR1A (0.67) | POLBLMNATACR1MAPTTSHR | |
| SCHEMBL8014785 | 0.78 | TACR1 (0.65) | POLBTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 611 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119033774-A | KL1333 composition and application thereof in preparation of tumor treatment drugs | 澳门大学 | 2024-11-29 | — | — | CN | claimed |
| CN-114264622-B | NO based on satellite-borne hyperspectral remote sensing technology2Method and device for quick response of concentration | 中国科学院合肥物质科学研究院 | 2024-07-23 | — | — | CN | claimed |
| CN-118222607-A | Soybean immunity negative regulation gene 6-phosphate trehalose synthase GmTPS, encoding protein and application thereof | 上海师范大学 | 2024-06-21 | — | — | CN | claimed |
| CN-117904013-A | Coli plasmid using steroid compound to induce resistance gene expression and application thereof | 中国科学院天津工业生物技术研究所 | 2024-04-19 | — | — | CN | claimed |
| WO-2023246464-A1 | USE OF CRYPTOTANSHINONE SUBSTANCE AND COMBINED COMPOSITION THEREOF | 澳门大学 | 2023-12-28 | — | — | WO | claimed |
| CN-116286702-A | Asparagus dehydrogenase mutant and application thereof | 鲁东大学 | 2023-06-23 | — | — | CN | claimed |
| CN-114264622-A | NO based on satellite-borne hyperspectral remote sensing technology2Method and device for quick response of concentration | 中国科学院合肥物质科学研究院 | 2022-04-01 | — | — | CN | claimed |
| CN-109880835-B | Recombinant H9N2 avian influenza virus strain, preparation method thereof, avian influenza vaccine and application thereof | 扬州大学 | 2022-03-25 | — | — | CN | claimed |
| US-20200397702-A1 | PHARMACEUTICAL COMPOSITIONS | SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (JP) | 2020-12-24 | — | — | US | claimed |
| US-20200147076-A1 | PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2020-05-14 | — | — | US | claimed |
| WO-2012148799-A1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-11-01 | — | — | WO | claimed |
| US-20080260848-A1 | Compositions that Enable Rapid-Acting and Highly Absorptive Intranasal Administration | TRANSLATIONAL RESEARCH, LTD., (JP) | 2008-10-23 | — | — | US | claimed |
| EP-1981502-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A CENTRAL OPIOID AGONIST, A CENTRAL OPIOID ANTAGONIST, AND A PERIPHERAL OPIOID ANTAGONIST, AND METHOD FOR MAKING THE SAME | Harrogate Holdings (BM) | 2008-10-22 | — | — | EP | claimed |
| WO-2007088489-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A CENTRAL OPIOID AGONIST, A CENTRAL OPIOID ANTAGONIST, AND A PERIPHERAL OPIOID ANTAGONIST, AND METHOD FOR MAKING THE SAME | HARROGATE HOLDINGS (US) | 2007-08-09 | — | — | WO | claimed |
| US-20070185145-A1 | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same | HARROGATE HOLDINGS (BM) | 2007-08-09 | — | — | US | claimed |
| EP-1785145-A1 | TRANSNASAL COMPOSITION HAVING IMMEDIATE ACTION AND HIGH ABSORBABILITY | Translational Research, Ltd. (JP) | 2007-05-16 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |